INBX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Inhibrx Biosciences's net margin of --. Inhibrx Biosciences's return on equity of 2616.46% beat CEL-SCI's return on equity of --.

Inhibrx Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1694.28%. Given that CEL-SCI has higher upside potential than Inhibrx Biosciences, analysts believe CEL-SCI is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are larger than CEL-SCI quarterly revenues of --. Inhibrx Biosciences's net income of -$43.9M is lower than CEL-SCI's net income of -$6.9M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.14x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Inhibrx Biosciences's net margin of -416.75%. Inhibrx Biosciences's return on equity of 2616.46% beat IGC Pharma's return on equity of -137.43%.

Inhibrx Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 950.42%. Given that IGC Pharma has higher upside potential than Inhibrx Biosciences, analysts believe IGC Pharma is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than IGC Pharma quarterly revenues of $412K. Inhibrx Biosciences's net income of -$43.9M is lower than IGC Pharma's net income of -$1.7M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.14x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 20.88x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Inhibrx Biosciences's net margin of -49.65%. Inhibrx Biosciences's return on equity of 2616.46% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Inhibrx Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Inhibrx Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Inhibrx Biosciences's net income of -$43.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.14x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Inhibrx Biosciences's net margin of 18.02%. Inhibrx Biosciences's return on equity of 2616.46% beat Protalix BioTherapeutics's return on equity of -29.54%.

Inhibrx Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 560.38%. Given that Protalix BioTherapeutics has higher upside potential than Inhibrx Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Inhibrx Biosciences.

Inhibrx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

Inhibrx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inhibrx Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Inhibrx Biosciences quarterly revenues are $100K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Inhibrx Biosciences's net income of -$43.9M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Inhibrx Biosciences's price-to-earnings ratio is 0.14x while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inhibrx Biosciences is -- versus 3.65x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.